Leukaemic stem cells: Drug resistance, metastasis and therapeutic implications

Malaysian Journal of Pathology

Volumn 34, Issue 2, 2012, Pages 77-88

  Wong, Rebecca S Y ^a   Cheong, Soon Keng ^b  

^a SEGI UNIVERSITY   (Malaysia)

^b UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Drug resistance; Leukaemic stem cells; Metastasis; Therapeutic targets

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CXCR4; IMATINIB; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SALL4; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BCR ABL GENE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL RENEWAL; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STEM CELL NICHE; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LEUKEMIA; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84872169359     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Porth CM. Disorders of white blood cells and lymphoid tissues. In: Porth CM, Matfin G, editors. Pathophysiology: Concepts of altered health states. 8th ed. Philadelphia: Wolters Kluwer Health; 2009.p. 313-18.
2. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant haematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101(12):4701-7.
3. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963; 199: 79-80.
4. Bonnet D, Dick JE. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive haematopoietic cell. Nat Med. 1997; 3 (7): 730-7.
5. Al-Hajj M, Clarke MF. Self-renewal and solid tumuor stem cells. Oncogene. 2004; 23: 7274-82
6. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumours Cancer Res. 2003; 63: 5821-8.
7. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med.2006; 355: 1253-61.
8. Krause DS, Van Etten RA. Right on target: eradicating leukaemic stem cells. Trends Mol Med. 2007; 12:470-81.
9. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.
10. Guzman Ml, Jordan CT. Considerations for targeting malignant stem cells in leukaemia. Cancer Control. 2004; 11 (2): 97-104.
11. Guzman ML, Upchurch D, Grimes B, et al. Expression of tumour-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukaemia cells. Blood. 2001; 97: 2177-9.
12. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood. 2001; 98: 2301-7.
13. Fialkow PJ, Jcobson RJ, Papayannopoulou T. Chronic myelocytic leukaemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977; 63:125-30.
14. Udosakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myeloid leukaemic cells in long-term culture due to a defect at the leukaemic stem cell level. Proc Natl Acad Sci USA. 1992; 89:6192-6.
15. Sirad C, Lapidot T, Vormoor J, et al. Normal and leukaemic SCID repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukaemic SRC are detected in blast crisis. Blood. 1996; 87: 1539-48.
16. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOC/SCID mice by primitive normal and leukaemic haematopoietic cells from patients with chronic myeloid leukaemia in chronic phase. Blood. 1998; 91: 2406-14.
17. Druker BJ, Guilhot F, O'Brien SG, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med. 2006; 355(23):2408-17.
18. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukaemia. N Engl J Med. 2003; 349(15):1423-32.
19. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukaemia after imatinib mesylate discontinuation. Haematologica. 2005; 90(7):979-81.
20. Jamieson CH. Chronic myeloid leukaemia stem cells. Haematology Am Soc Haematol Educ Program. 2008; 436-42.
21. Cobaleda C. Gutiérrez-Cianca N, Pé rez-Losada J, et al. A primitive haematopoietic cell is the target for the leukaemic transformation in human Philadelphia-positive acute lymphoblastic leukaemia. Blood. 2000; 95:1007-13.
22. George AA, Franklin J, Kerkof K, et al. Detection of leukaemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukaemia. Blood. 2001;97(12):3925-30.
23. Hope KJ, Jin L, Dick JE. Acute myeloid leukaemia originates from a hierarchy of leukaemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004; 5: 738-43.
24. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-84.
25. Lane WS, Scadden DT, Gilland DG. The leukaemic stem cell niche-current concepts and therapeutic opportunities. Blood. 2009; 114(6): 1150-7.
26. Yi J, Chen J, Sun J, Wei HL. The relationship between multi-drug resistance and proportion of leukaemia stem cells and expression of drug transporters in drug-resistant leukaemia K562/ ADM cells. Zhonghua Yi Xue Za Zhi. 2009; 89(25): 1741-4.
27. Jeong HW, Cui W, Yang Y, et al. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS ONE. 2011; 6(4): e18372.
28. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17 (1): 9-26.
29. Logan C. W, Nusse R. The Wnt signaling pathway in development and disease. Cell Dev Bio. 2004; 20: 781-810.
30. Yeung J, Esposito MT, Gandillet A, et al.-Catenin mediates the establishment and drug resistance of MLL leukaemic stem cells. Cancer Cell. 2010; 18(6):606-18.
31. Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF. CD27 signaling on chronic myelogenous leukaemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest. 2012; 122(2): 624-38.
32. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30(2):193-204.
33. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106(13):4261-8.
34. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/ forkhead transcription factors. Genes Dev. 2000; 14(2):142-6.
35. Accili D, Arden KC. FOXOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004; 117(4):421-6.
36. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005; 24:7410-25.
37. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signaling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80.
38. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008; 22:2454-72.
39. Kobune M, Takimoto R, Murase K, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukaemic cells. Cancer Sci. 2009;100(5):948-55.
40. She MR, ChenXL. Targeting signal pathways active in leukemic stem cells to overcome drug resistance, In: Shostak S, editor. Cancer stem cells theories and practice. Croatia; InTech; 2011. p. 404. [cited 2012 July 6] Available from: http://www.intechopen.com/ books/cancer-stem-cells-theories-and-practice
41. Han BW, Feng DD, Li ZG, et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet. 2011; 20(24):4903-15.
42. Lessard, J, Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature.2003; 423, 255-60.
43. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapyresistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25: 1315-21.
44. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukaemic stem cells. Nat Med. 2006;12(10):1167-74.
45. Funayama K, Murai F, Shimane M, Nomura H, Asano S. Adhesion-induced drug resistance in leukaemia stem cells. Pharmacology. 2010;86(2):79-84.
46. Welch JS, Martin MG. Leukaemias. In: Cashen AF, Wildes TM, Henderson KE, De Fer TM, editors. The Washington manual subspecialty consult series: Haematology and oncology subspecialty consult. Philadelphia; Lippincott Williams & Wilkins; 2008. p. 308-22.
47. Shah NP. Medical treatment of chronic myeloid leukaemia. Haematology Am Soc Haematol Educ Program. 2007; 371-5.
48. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukaemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011; 121(1):396-409.
49. Herman PC, Huber SL, Heeschen C. Metastatic cancer stem cells: A new target for anti-cancer therapy? Cell Cycle. 2008; 7(2): 188-193.
50. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signaling, locomotion, chemotaxis and adhesion. J MolHistol. 2004; 35: 233-45.
51. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005; 23: 879-94.
52. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukaemia. Blood. 2007; 109(2): 786-91.
53. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukaemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64(8):2817-24.
54. Deng CH, Zhang QP. Leukaemia stem cells in drug resistance and metastasis. Chin Med J. 2010; 123(7):954-60.
55. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820-7.
56. Zhou BG, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc London. 2007; 362 (1482):959-71.
57. Styczynski J, Drewa T. Leukaemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochimica Polonica. 2007; 54(4): 717-26.
58. Chumsri S, Matsui W, Burger AM. Therapeutic implications of leukaemic stem cell pathways. Clin Cancer Res. 2007;13(22 Pt 1):6549-54.
59. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers. 2010; 2: 1576-96.
60. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLLAF9 leukaemia. Cancer Cell. 2008;13(6):483-95.
61. Järås M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A. 2010; 107(37):16280-5.
62. Hauswirth AW, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34+/CD38-/ CD123+ AML stem cells. Eur J Clin Invest. 2007;37(1):73-82.
63. Herrmann H, Cerny-Reiterer S, Gleixner KV, et al. CD34(+)/CD38(-) stem cells in chronic myeloid leukaemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ ozogamicin. Haematologica. 2012;97(2):219-26.
64. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukaemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198-208.
65. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukaemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215-24.
66. Kadowaki N, Kitawaki T. Recent advances in antigen-specific immunotherapy for acute myeloid leukaemia. Clin Dev Immunol. 2011; 2011: Article ID 104926, 7 pages.
67. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukaemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006; 91(12):1653-61.
68. Thomas X. Targeting leukaemia stem cells: The new goal of therapy in adult acute myeloid leukemia. World J Stem Cells. 2009; 1(1): 49-54.
69. Lindner I, Kharfan-Dabaja MA, Ayala E, et al. Induced dendritic cell differentiation of chronic myeloid leukaemia blasts is associated with down-regulation of BCR-ABL. J Immunol. 2003; 171(4):1780-91.
70. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukaemia. Cytotherapy. 2012;14(6):647-56.
71. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukaemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010; 107(31):13824-9.